Compare Dicks Sporting Goods Inc (DKS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs TG Therapeutics Inc — how do they compare? Dicks Sporting Goods Inc trades at $136.64 (market cap $13.26B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Dicks Sporting Goods Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and TG Therapeutics Inc for 16 Days on average.
| DKS | TGTX | |
|---|---|---|
Market Cap | $13.26B | $8.16B |
Volume | 2,292,035 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $59.06 |
52-Week Low | $121.15 | $26.94 |
Typical Hold Time | 19 Days | 16 Days |
Enterprise Value | $20.31B | $8.37B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $135.99, up 3.67% today, with a bearish technical signal but strong fundamentals including a P/E of 14.86 and ROE of 18.47%. Recent earnings show mixed results, with a Q2 2026 miss, while revenue grew to $13.44B in 2025. The stock faces headwinds from a securities class action lawsuit, but analysts maintain a buy consensus with a $153.30 price target.
The outlook is cautious due to legal risks and a bearish technical trend, but solid profitability and valuation metrics offer support. Upside potential exists if legal issues resolve and earnings rebound, though investor sentiment is tempered by near-term uncertainties. Risks include litigation outcomes and competitive pressures in retail.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
